What are the considerations for selecting and dosing opioids in patients with acute or chronic pain, including those with a history of substance abuse or respiratory disease?

Opioid Pharmacokinetics and Selection for Acute and Chronic Pain

Direct Answer: Selecting the Right Opioid

For acute severe pain in opioid-naïve patients, use immediate-release morphine or hydromorphone titrated every 5 minutes, or fentanyl titrated every 3 minutes, with the choice driven by onset time requirements and patient-specific factors including respiratory disease and substance abuse history. 1, 2

---

Pharmacokinetic Properties by Agent

Morphine

• Onset: Relative onset approximately 6 minutes IV 2
• Peak effect delay: 1.6-4.8 hours (though clinical significance is minimal) 2
• Duration: 96 minutes 2
• Titration protocol: 0.1 mg/kg IV, then 0.05 mg/kg every 5 minutes achieves pain control in 40% at 10 minutes and 76% at 60 minutes 2
• Indication: First-line for moderate to severe acute pain in opioid-naïve patients 1, 3

Hydromorphone

• Onset: Relative onset approximately 5 minutes IV 2
• Peak effect delay: 18-38 minutes (oral formulation) 2
• Duration: 120 minutes 2
• Titration protocol: Can be titrated IV every 5 minutes until adequate pain control 2
• Special consideration: High-potency opioid carrying highest risks of overdose and addiction 4

Fentanyl

• Onset: Relative onset approximately 2 minutes IV 2
• Peak effect delay: 16.4 minutes 2
• Duration: 7 minutes (shortest of the three) 2
• Titration protocol: 0.1 µg/kg IV every 3 minutes 2
• Transdermal formulation: Only for opioid-tolerant patients requiring continuous around-the-clock therapy; contraindicated for acute or postoperative pain 5
• Opioid tolerance requirement: Patients must be taking ≥60 mg oral morphine daily, ≥30 mg oral oxycodone daily, or ≥8 mg oral hydromorphone daily for ≥1 week 5

Methadone

• Special pharmacokinetics: Long and variable half-life with peak respiratory depression occurring later and lasting longer than peak analgesic effect 4
• Cardiac risk: Associated with QT prolongation and cardiac arrhythmias 4
• Overdose risk: Specifically associated with increased overdose risk compared to short-acting formulations 4
• Naloxone requirement: Requires prolonged naloxone infusions (24-72 hours or longer) if overdose occurs due to extended half-life 6

---

Clinical Decision Algorithm for Opioid Selection

Step 1: Assess Pain Severity and Opioid Status

Opioid-Naïve Patients:

• Severe pain (7-10/10): Rapid titration of short-acting opioids (morphine, hydromorphone, or fentanyl) 1
• Moderate pain (4-6/10): Slower titration of short-acting opioids 1
• Mild pain (1-3/10): NSAIDs or acetaminophen first; consider slower titration of short-acting opioids only if nonopioids fail 1

Opioid-Tolerant Patients:

• Breakthrough pain ≥4/10: Calculate previous 24-hour total opioid requirement; rescue dose = 10-20% of total daily dose 1
• **Reassess every 60 minutes for oral opioids, every 15 minutes for IV opioids 1
• If pain unchanged after 2-3 cycles: Consider route change from oral to IV or alternative strategies 1

Step 2: Consider Respiratory Disease

Contraindications and High-Risk Situations:

• Significant COPD or cor pulmonale: Use extreme caution; consider alternative non-opioid analgesics first 5
• Substantially decreased respiratory reserve, hypoxia, or hypercapnia: Even therapeutic doses may cause apnea; employ opioids only at lowest effective dose under careful supervision 5
• Central sleep apnea: Specific risk factor for opioid overdose requiring increased monitoring 4
• If opioids necessary: Choose shortest-acting agent (fentanyl) with most frequent monitoring; avoid long-acting formulations entirely 4, 5

Step 3: Evaluate Substance Abuse History

Risk Assessment:

• Active or previous substance abuse (including alcoholism) or family history: Higher likelihood of opioid misuse and abuse 1
• Mental illness (e.g., major depression): Increased risk requiring intensive monitoring 5

Management Strategy:

• **Use lowest effective dosage with increased monitoring frequency 1, 5
• **Prescribe naloxone for home use and provide family training on administration 4, 7
• **Avoid long-acting formulations initially; use immediate-release opioids with more frequent reassessment 1
• **Implement urine drug screens and greater patient/family education about overdose risks 4

---

Dosing Principles and Titration

Acute Pain Management

Initial Dosing:

• **Start at lowest effective dosage 1
• **Prescribe immediate-release opioids, not extended-release 1
• Duration: 3 days or less often sufficient; more than 7 days rarely needed 1
• **Prescribe "as needed" rather than scheduled dosing (e.g., "one tablet every 4 hours as needed" not "one tablet every 4 hours") 1

Titration Frequency:

• Morphine/hydromorphone: Every 5 minutes until adequate control 2
• Fentanyl: Every 3 minutes 2
• Oral opioids: Reassess every 60 minutes 1
• IV opioids: Reassess every 15 minutes 1

Chronic Pain Management

Transition to Long-Acting Formulations:

• **Only after stable pain control achieved with short-acting opioids 1
• **Provide round-the-clock extended-release formulation with rescue doses for breakthrough pain 1
• Rescue dose: 10-20% of total daily dose, given every hour as needed 1
• **Repeated need for rescue doses per day indicates need to adjust baseline treatment 1

Dose Escalation Precautions:

• ≥50 MME/day: Implement additional precautions including increased follow-up frequency and consider offering naloxone 1
• ≥90 MME/day: Avoid or carefully justify based on individualized assessment; if no improvement in pain and function, discuss tapering 1
• Doses >80-100 MME: Disproportionately associated with overdose-related hospital admissions and deaths 4

---

Critical Safety Considerations

Drug Interactions Requiring Dose Reduction

CNS Depressants:

• Benzodiazepines, alcohol, sedative-hypnotics, antihistamines: Dramatically increase overdose risk; significantly reduce dose of one or both agents 4, 5
• Antipsychotics: FDA black box warning for serious effects including respiratory depression and death when combined with opioids 7

CYP3A4 Inhibitors:

• Examples: Ritonavir, ketoconazole, clarithromycin, erythromycin, grapefruit juice, verapamil 5
• Effect: Increase fentanyl plasma concentrations, potentially causing fatal respiratory depression 5
• Management: Careful monitoring for extended period with dosage adjustments as warranted 5

Renal and Hepatic Dysfunction

• Impaired clearance: Leaves higher and longer-lasting drug levels, increasing overdose risk 4
• Tramadol: Older patients and those with renal/hepatic dysfunction more prone to accumulation; maintain lower dosages (maximum 400 mg/day in healthy adults, less in dysfunction) 1

Monitoring Requirements

Initial Phase (First 24-72 Hours):

• **Highest risk period for respiratory depression, especially with fentanyl transdermal 5
• **Monitor respiratory rate, depth, and level of consciousness 7
• **Use pulse oximetry when clinically indicated, but do not rely solely on it as oxygen saturation may remain normal despite significant hypoventilation 7

Ongoing Monitoring:

• **Evaluate benefits and harms within 1-4 weeks of starting or dose escalation 1
• **Continue evaluation every 3 months or more frequently 1
• **If benefits do not outweigh harms, optimize other therapies and taper opioids 1

---

Management of Adverse Effects

Constipation

• **Anticipate and treat prophylactically with stimulating laxative to increase bowel motility, with or without stool softeners 1
• **Titrate laxative dose as opioid dose escalates 1

Nausea

• **Often transient; treat with antiemetics (prochlorperazine or metoclopramide) 1
• **If persistent, try different opioid 1

Sedation

• **Often transient until tolerance develops (days to weeks) 1
• **If persistent >30 minutes, assess for other causes (CNS pathology, hypercalcemia, dehydration, sepsis, hypoxia) 7
• **Consider opioid rotation, dose reduction, or addition of stimulants (caffeine 100-200 mg every 3-4 hours, methylphenidate 5-10 mg 1-3 times daily) 1

Respiratory Depression

Treatment Protocol:

• **Dilute naloxone 0.4 mg in 9 mL normal saline (total 10 mL) 1
• **Give 2 mL (0.04-0.08 mg) every 30-60 seconds until improvement 1
• For short-acting opioids: Observe ≥2 hours after complete naloxone discontinuation 6
• For methadone: Continue observation 24-72 hours or longer 6
• Caution in opioid-tolerant patients: Administer naloxone cautiously to avoid precipitating acute withdrawal 7

---

Special Populations and Contexts

Procedure-Related Pain

• **Acute short-lived experience often accompanied by anxiety 1
• **Use short-acting opioids with rapid onset (fentanyl preferred for 2-minute onset) 2
• **Consider anxiolytics in addition to analgesics 1

Cancer Pain

• Adjuvant analgesics: Consider for all patient groups to enhance opioid effects 1
• Neuropathic pain: May require tricyclic antidepressants, anticonvulsants, or corticosteroids in addition to opioids 1

End-of-Life Care

• **At comfort measures only, slowed respiration is expected and naloxone may be inconsistent with goals of care 7
• **Palliative sedation for refractory suffering is distinct from euthanasia 1

---

Common Pitfalls to Avoid

1. Do not prescribe extended-release or long-acting opioids for acute pain 1, 5
2. Do not prescribe fentanyl transdermal to opioid-naïve patients 5
3. Do not ignore PRN medication patterns—frequent use suggests inadequate baseline control 7
4. Do not combine opioids with benzodiazepines or alcohol without significant dose reduction 4, 5
5. Do not fail to prescribe prophylactic bowel regimen 1
6. Do not prescribe additional opioids "just in case" pain continues longer than expected 1
7. Do not increase doses to ≥90 MME/day without careful justification and consideration of tapering 1